Biden administration to retire 'Operation Warp Speed' name
The incoming Biden administration said that it will no longer use the "Operation Warp Speed" term to describe the U.S. government's efforts to combat the COVID-19 pandemic.
Precision Medicine acquires Project Farma
Precision Medicine has acquired Project Farma, a bioengineering services firm.
Thermo Fisher closes Henogen acquisition
Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million euros ($876 million U.S.) in cash.
Gamma Biosciences to acquire BioMagnetic Solutions
Gamma Biosciences has agreed to acquire BioMagnetic Solutions, a next-generation cell selection and bioseparation technology company.
Cognate BioServices expands manufacturing in U.S., Europe
Contract development and manufacturing organization Cognate BioServices plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and to increase office support at its facilities in the U.S. and Europe.
RoosterBio, Sartorius partner on cell and gene therapy manufacturing
RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cells manufacturing for regenerative medicines.
Nucleai and Debiopharm team up in AI-based cancer drug development
Biomarker discovery company Nucleai will be working with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per a new research collaboration.
Fujifilm secures funding, signs lease for new research/manufacturing center
Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and that a lease for a site in the Boston area has been signed.
Startup Creative Bio launches cell culture portfolio
Creative Bio has launched a portfolio of cell culture tools that it hopes will be useful during the COVID-19 pandemic.
Thermo Fisher subsidizes more sequencers for global coronavirus research
Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new strains of the virus and for tracing community transmission.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter